ABT Stock Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Abbott Laboratories Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$117.76 |
| 52 Week High | US$121.64 |
| 52 Week Low | US$99.71 |
| Beta | 0.72 |
| 11 Month Change | 0.64% |
| 3 Month Change | 4.50% |
| 1 Year Change | 14.47% |
| 33 Year Change | -6.45% |
| 5 Year Change | 37.81% |
| Change since IPO | 32,056.33% |
Recent News & Updates
Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist
Oct 31
Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Oct 21Recent updates
Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist
Oct 31Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Oct 21Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Oct 14Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Oct 11Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price
Sep 27Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Sep 11A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Aug 16Abbott Laboratories: Driving Value By Scaling Innovations
Aug 13Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
Aug 05Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough
Jul 13These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price
Jun 18Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)
Jun 04Abbott Laboratories: Why I Agree With Wall Street On This One
Jun 04Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26Shareholder Returns
| ABT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.6% | 1.5% | 2.2% |
| 1Y | 14.5% | 20.9% | 31.7% |
Return vs Industry: ABT underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: ABT underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| ABT volatility | |
|---|---|
| ABT Average Weekly Movement | 2.5% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABT's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1888 | 114,000 | Robert Ford | www.abbott.com |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Abbott Laboratories Fundamentals Summary
| ABT fundamental statistics | |
|---|---|
| Market cap | US$203.38b |
| Earnings (TTM) | US$5.74b |
| Revenue (TTM) | US$41.22b |
35.6x
P/E Ratio5.0x
P/S RatioIs ABT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABT income statement (TTM) | |
|---|---|
| Revenue | US$41.22b |
| Cost of Revenue | US$18.17b |
| Gross Profit | US$23.04b |
| Other Expenses | US$17.30b |
| Earnings | US$5.74b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.31 |
| Gross Margin | 55.91% |
| Net Profit Margin | 13.94% |
| Debt/Equity Ratio | 37.6% |
How did ABT perform over the long term?
See historical performance and comparison